Compare Incyte Corporation (INCY) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Williams Companies Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Williams Companies Inc trades at $74.05 (market cap $90.70B). The key difference: Williams Companies Inc is far larger — about 3.9× Incyte Corporation's market cap, and Williams Companies Inc pays a 2.83% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | WMB | |
|---|---|---|
Market Cap | $23.11B | $90.70B |
Sector | Health | Energy |
52-Week High | $118.52 | $79.40 |
52-Week Low | $67.38 | $56.51 |
Enterprise Value | $19.13B | $120.08B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
WMB trades at $74.57, up 1.62% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $11.95B in 2025 with a net income margin of 23.4% and recently secured a $5.34 billion Blackstone-led investment for power projects. Analyst consensus is strongly bullish with a $86.00 price target and 79% buy ratings.
The outlook is supported by strategic investments in energy infrastructure and stable cash flows, but risks include high debt levels and sensitivity to natural gas prices. The stock offers a dividend yield and growth potential from LNG expansion, though recent earnings misses warrant monitoring execution on new projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
